150 related articles for article (PubMed ID: 10841836)
1. Re: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.
Ménard S; Tagliabue E; Campiglio M; Balsari A
J Natl Cancer Inst; 2000 Jun; 92(11):943-4. PubMed ID: 10841836
[No Abstract] [Full Text] [Related]
2. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.
Radmacher MD; Simon R
J Natl Cancer Inst; 2000 Jan; 92(1):48-53. PubMed ID: 10620633
[TBL] [Abstract][Full Text] [Related]
3. How is tamoxifen's action subverted?
Jordan VC
J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
[No Abstract] [Full Text] [Related]
4. [Current issues in adjuvant hormone therapy of breast cancer].
Semiglazov VF; Semiglazov VV
Vopr Onkol; 2003; 49(6):771-5. PubMed ID: 14976929
[No Abstract] [Full Text] [Related]
5. Tamoxifen: an enduring star.
Veronesi U; Maisonneuve P; Decensi A
J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
[No Abstract] [Full Text] [Related]
6. Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
Narasimhadevara R; Pollak MN; Foulkes WD
J Natl Cancer Inst; 2003 Jun; 95(12):917; author reply 918-9. PubMed ID: 12813177
[No Abstract] [Full Text] [Related]
7. Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy.
Ferretti G; Felici A; Cognetti F
J Natl Cancer Inst; 2007 Nov; 99(21):1644; author reply 1644-6. PubMed ID: 17971534
[No Abstract] [Full Text] [Related]
8. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
Hu JC; Mokbel K
Eur J Surg Oncol; 2001 Jun; 27(4):335-7. PubMed ID: 11417974
[No Abstract] [Full Text] [Related]
9. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Vakaet L
J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
[No Abstract] [Full Text] [Related]
10. Targeting breast cancer with hormonal treatment options.
Mellington TE; Fields MM
Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
[No Abstract] [Full Text] [Related]
11. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
12. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
Lash TL; Gurwitz JH; Silliman RA
J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
[TBL] [Abstract][Full Text] [Related]
13. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
14. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Raina V
Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
[No Abstract] [Full Text] [Related]
15. [Estrogen and progesterone receptors in breast cancer].
Sonoo H
Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988
[No Abstract] [Full Text] [Related]
16. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu K; Brown P
J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
[No Abstract] [Full Text] [Related]
17. Tamoxifen, mammographic density, and breast cancer prevention.
Boyd NF
J Natl Cancer Inst; 2011 May; 103(9):704-5. PubMed ID: 21487099
[No Abstract] [Full Text] [Related]
18. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
20. [2nd European Breast Cancer Conference, Bruxelles, September 26-30, 2000. Interview with Anthony Howell].
Howell A
Tumori; 2000; 86(6):A1-4. PubMed ID: 11271673
[No Abstract] [Full Text] [Related]
[Next] [New Search]
